pharma news today glp-1 obesity drugs such as semaglutide and tirzepatide are transforming and diabetes care in India, but experts warn that improper use could lead to significant muscle loss. A new India-specific consensus highlights glp-1 obesity drug news october

Its always easier to adjust your lifestyle, rather than change it entirely

Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes

In the main analysis, assuming no cardiovascular mortality benefit, the ICER was $437 400 per QALY gained (the study pooled patients with and without diabetes), at an annual cost of $3920

Live-statistik, tydelig oddsbevgelse og historik over dine placeringer giver bedre beslutningsgrundlag

The VITAL trial found a borderline reduction in cancer mortality with vitamin D supplementation, while other trials have shown mixed results for cancer incidence

As with injections, the Wegovy pill mimics the effects of a gut hormone called GLP-1, released after eating, which regulates appetite and signals a feeling of fullness